Patents by Inventor Heinz Altmann

Heinz Altmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5948898
    Abstract: Compositions and methods are provided for modulating the expression of protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. The oligonucleotides contain a methoxyethoxy (--O--CH.sub.2 CH.sub.2 OCH.sub.3) modification at the 2' position of at least one nucleotide. Methods of inhibiting PKC expression and methods of treating conditions associated with expression of PKC using oligonucleotides of the invention are disclosed.
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: September 7, 1999
    Assignees: ISIS Pharmaceuticals, Inc., Ciba-Geigy AG
    Inventors: Nicholas M. Dean, Pierre Martin, Karl-Heinz Altmann
  • Patent number: 5919773
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human c-raf and capable of inhibiting raf expression. The oligonucleotides contain a methoxyethoxy (2'--O--CH.sub.2 CH.sub.2 OCH.sub.3) modification at the 2' position of at least one nucleotide. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating abnormal proliferative conditions which employ oligonucleotides of the invention.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: July 6, 1999
    Assignees: Isis Pharmaceuticals, Inc., Ciba-Geigy, Ltd.
    Inventors: Brett P. Monia, Pierre Martin, Karl-Heinz Altmann
  • Patent number: 5744460
    Abstract: The invention relates to combinations of PKC-targeted (especially PKC-.alpha.-targeted) deoxyribo- and ribo-oligonucleotides and derivatives thereof with other chemotherapeutic compounds, as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to such oligonucleotides or oligonucleotide derivatives, especially to to modulation of the activity of a regulatory protein.
    Type: Grant
    Filed: March 7, 1996
    Date of Patent: April 28, 1998
    Assignee: Novartis Corporation
    Inventors: Marcel Muller, Thomas Geiger, Karl-Heinz Altmann, Doriano Fabbro, Nicholas M. Dean, Brett Monia, Clarence Frank Bennett
  • Patent number: 5744362
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human c-raf and capable of inhibiting raf expression. The oligonucleotides contain a methoxyethoxy (2'-O--CH.sub.2 CH.sub.2 OCH.sub.3) modification at the 2' position of at least one nucleotide. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating abnormal proliferative conditions which employ oligonucleotides of the invention.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 28, 1998
    Assignees: Isis Pharmaceuticals, Inc., Ciba-Geigy, Ltd.
    Inventors: Brett P. Monia, Pierre Martin, Karl-Heinz Altmann
  • Patent number: 5700920
    Abstract: Compounds of the formulae I and Ia and their racemates ##STR1## in which A is --CH.sub.2 -- or --CH.sub.2 CH.sub.2 --, R.sub.1 is hydrogen or a protective group, R.sub.2 is hydrogen or a protective group or a radical forming a phosphorus-containing nucleotide bridge group and B is a purine or pyrimidine radical or an analogue thereof, can be used as antiviral active ingredients or for the preparation of biologically active oligonucleotides.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 23, 1997
    Assignee: Novartis Corporation
    Inventors: Karl-Heinz Altmann, Rene Imwinkelried, Albert Eschenmoser
  • Patent number: 5610300
    Abstract: Compounds of the formulae I and Ia and their racemates ##STR1## in which A is --CH.sub.2 -- or --CH.sub.2 CH.sub.2 --, R.sub.1 is hydrogen or a protective group, R.sub.2 is hydrogen or a protective group or a radical forming a phosphorus-containing nucleotide bridge group and B is a purine or pyrimidine radical or an analogue thereof, can be used as antiviral active ingredients or for the preparation of biologically active oligonucleotides.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 11, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: Karl-Heinz Altmann, Ren e Imwinkelried, Albert Eschenmoser
  • Patent number: 5461152
    Abstract: Compounds of the formulae I and Ia and their racemates ##STR1## in which A is --CH.sub.2 -- or --CH.sub.2 CH.sub.2 --, R.sub.1 is hydrogen or a protective group, R.sub.2 is hydrogen or a protective group or a radical forming a phosphorus-containing nucleotide bridge group and B is a purine or pyrimidine radical or an analogue thereof, can be used as antiviral active ingredients or for the preparation of biologically active oligonucleotides.
    Type: Grant
    Filed: June 28, 1993
    Date of Patent: October 24, 1995
    Assignee: Ciba-Geigy Corporation
    Inventors: Karl-Heinz Altmann, Rene Imwinkelried, Albert Eschenmoser
  • Patent number: 4560496
    Abstract: A mixture consisting essentially of 5-40 mol-% of component B and the balance component A, component B consisting essentially of 5-n-propyl-2-(4-cyanophenyl)-1,3 dioxane and component A consisting essentially of 60-70 mol-% of 4-n-butylcyclohexanecarboxylic acid and 30-40 mol-% of 4-n-hexylcyclohexanecarboxylic acid, has superior liquid crystal properties for use in electrooptical devices.
    Type: Grant
    Filed: September 26, 1984
    Date of Patent: December 24, 1985
    Inventors: Dietrich Demus, Horst Zaschke, Heinz Altmann, Michael Keil
  • Patent number: 4490278
    Abstract: The invention relates to liquid crystal nematic substances for electro-optical devices for the modulation of light, for the reproduction of numerals, signs and images as well as an orienting medium for spectroscopy and gas chromatography.It was found that compounds containing two or three rings, connected by carboxyl groups are new liquid crystal nematic substances of the general formula ##STR1## where R.sup.1 =C.sub.n H.sub.2n+1, CN; R.sup.2 =C.sub.m H.sub.2m+1, CN;R.sup.3 =H, CH.sub.3, C.sub.2 H.sub.5 Cl, Br; x=0 or 1; m,n=numbers from 1 to 10 are suitable for electro-optical arrangements for the modulation of transmitted or reflected light as well as for the reproduction of numeral signals and images, and further, as an orienting medium for spectroscopy and gas chromotography.Other liquid crystal substances or non-liquid crystalline substances, particularly dyes, may be added to the substances according to the invention.
    Type: Grant
    Filed: September 22, 1980
    Date of Patent: December 25, 1984
    Inventors: Herrmann Schubert, Hans-Joachim Deutscher, Horst Kresse, Dietrich Demus, Heinz Altmann, Marlies Korber, Ute Bottger